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SUMMARY 
Cancer adoptive cell therapy (ACT) relies on the infusion of immune cell populations mediating 
direct antitumor effects, such as cytotoxic CD8+ T lymphocytes (CTL), natural killer (NK) cells and 
Cytokine-Induced Killer (CIK) cells. In this study, we aimed at improving CIK cell potential for 
adoptive immunotherapy strategies. CIK cells are a heterogeneous population of ex vivo expanded 
lymphocytes, which share phenotypic and functional features with both NK and T cells. They exert a 
potent MHC-independent antitumor activity against both hematological and solid malignancies, but 
not normal tissues and hematopoietic precursors. Several clinical trials have demonstrated the 
feasibility and the therapeutic efficacy together with low toxicity of CIK cells infusion, supporting CIK 
cells as a very promising cell population for adoptive immunotherapy. In this work, CIK cells were 
obtained from PBMCs of healthy donors by the timed addition of IFN-γ, anti-CD3 antibody and IL-2. 
Analyzing their phenotype, we demonstrated for the first time a relevant expression of CD16 in a 
donor-dependent manner and, based on this observation, we proved the ability of CIK cells to kill 
tumors by an Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) mechanism. Indeed, the 
concurrent administration of clinically therapeutic mAbs, such as trastuzumab or cetuximab, led to a 
significant improvement of their antitumor activity in vitro against both ovarian and breast cancer 
cell lines. To formally prove that the CD16 receptor is functional and directly involved in the ADCC, 
an anti-CD16 blocking antibody was added to the assays. NK cell depletion from bulk cultures 
confirmed that the ADCC activity is accountable to the CIK CD16+ subpopulation. This novel function 
of CIK cells, never exploited before, was assessed for therapeutic efficacy in mouse models of 
human ovarian carcinoma xenografted in NOD/SCID common γ chain knockout (NSG) mice. Co-
administration of CIK cells and mAbs significantly increased the survival of tumor-bearing mice, as 
compared to animals receiving CIK cells alone. CIK cell antitumor activity in vitro was also enhanced 
by the combination with bispecific antibodies and immunoligands, which are able to target both a 
tumor-associated antigen and activating receptors expressed by effector cells. Taken together, these 
data envisage new perspectives for adoptive immunotherapy where antigen-specific retargeting of T 
cells can be achieved by a combination therapy with clinical-grade monoclonal antibodies already 
widely used in cancer therapy, and CIK cell populations that are easily expandable in very large 
numbers, inexpensive, safe and do not require genetic manipulations. In conclusion, this new 
therapeutic strategy for the ACT treatment of different types of tumors could find wide 
implementation and application, and be expanded to the use of additional therapeutic antibodies. 
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RIASSUNTO 
La terapia cellulare adottiva (Adoptive Cell Therapy, ACT) si basa sulla somministrazione di 
popolazioni di cellule immunitarie in grado di mediare un effetto antitumorale in modo diretto, ad 
esempio linfociti T CD8+ citotossici (CTL), cellule natural killer (NK) e cellule killer indotte da citochine 
(Cytokine-Induced Killer cells, CIK). Lo scopo di questo lavoro è stato quello di incrementare il 
potenziale delle cellule CIK nelle strategie di immunoterapia adottiva. Le cellule CIK sono una 
popolazione eterogenea di linfociti espansi ex vivo che condividono caratteristiche fenotipiche e 
funzionali sia con le cellule NK sia con le cellule T. Queste cellule esercitano una potente citotossicità 
MHC-indipendente nei confronti di tumori sia ematologici sia solidi, ma non di tessuti normali e 
precursori ematopoietici. Diversi trial clinici hanno dimostrato l’attuabilità, l’efficacia terapeutica e 
la bassa tossicità delle infusioni di cellule CIK, supportandole come popolazione cellulare molto 
promettente per l’immunoterapia adottiva. In questo lavoro, le cellule CIK sono state ottenute da 
cellule mononucleate del sangue periferico (Pheripheral Blood Mononuclear Cells, PBMCs) di 
donatori sani mediante l’aggiunta di interferone gamma (Interferon-, IFN-), anticorpi anti-CD3 e 
interleuchina 2 (Interleukin-2, IL-2). Analizzando il fenotipo, abbiamo dimostrato per la prima volta 
una rilevante espressione donatore-dipendente del recettore CD16 e, basandoci su questa 
osservazione, abbiamo analizzato la capacità delle cellule CIK di uccidere cellule tumorali mediante 
citotossicità cellulo-mediata anticorpo-dipendente (Antibody-Dependent Cell-mediated Cytotoxicity, 
ADCC). Infatti, abbiamo osservato che la simultanea somministrazione di anticorpi monoclonali 
terapeutici, come il trastuzumab e il cetuximab, portano ad un significativo incremento dell’attività 
antitumorale in vitro delle CIK nei confronti di linee cellulari di tumore ovarico e mammario. Per 
dimostrare che il CD16 è funzionale ed è direttamente coinvolto nell’ADCC, è stato aggiunto al 
saggio un anticorpo bloccante anti-CD16. La deplezione delle cellule NK ha confermato che l’ADCC è 
attribuibile alla sottopopolazione CD16+ delle cellule CIK. Questa nuova funzione delle cellule CIK, 
descritta qui per la prima volta, è stata valutata per la sua efficacia terapeutica in un modello murino 
di carcinoma ovarico umano trapiantato in topi NOD/SCID knockout per la catena comune (topi 
NSG). La co-somministrazione di cellule CIK e anticorpi monoclonali ha aumentato 
significativamente la sopravvivenza dei topi con tumore, in confronto ai topi trattati soltanto con le 
CIK. Inoltre, l’attività antitumorale in vitro delle cellule CIK è stata incrementata mediante la 
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combinazione con anticorpi bispecifici e immunoligandi, in grado di legare contemporaneamente un 
antigene associato al tumore e un recettore attivatore espresso dalle cellule effettrici.  
Complessivamente, questi dati prospettano nuove possibilità per l’immunoterapia adottiva, in cui il 
reindirizzamento antigene-specifico dei linfociti T può essere ottenuto mediante la combinazione di 
anticorpi monoclonali di utilizzo clinico, già ampiamente utilizzati per la terapia antitumorale, con 
popolazioni di cellule CIK, che sono facilmente espandibili, economiche, sicure e non richiedono 
manipolazioni genetiche. In conclusione, questa nuova strategia terapeutica per trattamento di 
diversi tipi di tumori mediante terapia cellulare adottiva potrà trovare ampie possibilità di 
implementazione e applicazione, e potrà essere estesa all’utilizzo di ulteriori anticorpi terapeutici. 
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INTRODUCTION 
Cancer immunotherapy 
Cancer is a major cause of mortality worldwide, and current standard cancer therapies, such as 
surgery, radiation and chemotherapy, are effective in a consistent fraction of patients by efficiently 
removing primary tumors. However, complete removal of malignant tissues is not always possible, 
conventional therapies becoming ineffective and often leading to a high toxicity, severe side effects 
and, eventually, to a relapse of the tumor. In this context, alternative approaches are indispensable; 
among these, cancer immunotherapy has shown promising results against different tumors, and 
the last few years have witnessed a renewed interest in targeting and eliminating cancer using 
immunologic strategies1.  
Cancer immunotherapy can be divided into active and passive approaches. Active immunotherapy 
aims at eliciting a specific host immune response by employing cancer vaccines or cytokines. The 
systemic delivery of cytokines, such as interleukin-2 (IL-2)2 and interferon-α (IFN-α)3, boosts 
immune responses through the recruitment and the induction of immune effector cells. Cancer 
vaccines stimulates patient’s own immune system to recognize and eliminate malignant cells, and 
can lead to immunological memory and long-lasting antitumor response4. Examples of antitumor 
vaccines are the prophylactic vaccines against hepatitis B virus (HBV), which prevents HBV-induced 
hepatocellular carcinoma5, and Gardasil® and Cervarix®, which protect against human 
papillomavirus (HPV)-induced cervical carcinoma6. Most recent vaccine strategies are dealing with 
therapeutic, rather than prophylactic, applications, to treat patients with already apparent tumors. 
Several strategies for cancer vaccination and vaccine delivery have been developed, such as 
recombinant proteins and peptides, viral vectors, pulsed dendritic cells (DC), DNA or RNA-based 
vaccines7,8. 
Passive immunotherapy involves the administration of therapeutic agents, such as monoclonal 
antibodies and effector cells, which can directly affect the tumor. Monoclonal antibodies can target 
tumor-expressed antigens, vascular growth factors, and tumor-associated stroma, inhibiting tumor 
cell growth9. However, recently, antibodies targeting immune checkpoints, such as PD-1 
(Programmed Death protein-1) and CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), have been 
developed. These antibodies are able to elicit a specific host immune response and, therefore, can 
not be considered as a passive, but rather active, immunotherapy approach.  
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Adoptive cell transfer (ACT) therapies are based on the administration of in vitro expanded, 
activated and, if necessary, genetically modified effector cells, such as TCR- or Chimeric Antigen 
Receptor (CAR)-transduced T lymphocytes10, Tumor-Infiltrating Lymphocytes (TIL)11, Natural Killer 
(NK) cells12, γδ T cells13, or Cytokine-Induced Killer (CIK) cells14,15. Depending on the cell type, the 
effectors can be obtained from donors (allogeneic cells) or from the patients themselves 
(autologous cells), and are armed to specifically eliminate tumor cells.   
Cell-based immunotherapy strategies have been proven to be highly effective against both 
hematological and solid malignancies in many clinical trials16. Three critical issues need to be 
addressed by all ACT strategies in order to be effective in clinical applications: first, sufficient 
numbers of immune effector cells must be obtained; second, they  must reach the tumor site and 
recognize the targets and third, kill the tumor cells17. The laborious and expensive production of 
effector cells, mostly restricted to autologous T-cell products, is an important disadvantage for T-
cell therapies and an impediment to their commercialization. These obstacles could be overcome 
by using CIK cells; they are a population of effector cells obtained from peripheral blood 
mononuclear cells (PBMCs) after ex vivo stimulation, which show unique and interesting features 
supporting their role as a promising tool for ACT approaches. 
Cytokine-Induced Killer (CIK) cells 
CIK cells are a heterogeneous population of ex vivo expanded lymphocytes capable of MHC-
unrestricted antitumor activity, which share phenotypic and functional features with both NK and T 
cells. These cells were first obtained by Schmidt-Wolf et al. in 1991 from PBMCs by the timed 
addition of IFN-γ, monoclonal antibodies directed against CD3 (OKT3) and IL-218. During the first 24 
hours, PBMCs are stimulated with interferon-γ (IFN-γ) that induces the expression of IL-2 receptors 
and increases cytotoxicity. On the next day, cells are exposed to a mitogenic signal by engagement 
of CD3 with OKT3 antibody, and further activated and maintained with IL-2 during the entire 
expansion phase. After 2-3 weeks of expansion, the bulk population is composed mainly by 
CD3+CD56+ CIK cells and CD3+CD56- T cells, and only a small fraction (<10%) of CD3-CD56+ NK cells 
(Figure 1)19.  
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Figure 1: CIK cell in vitro generation and expansion. CIK cells are obtained from healthy 
donor PBMCs and expanded ex vivo. Cells are stimulated by the timed addition of IFN-γ, anti-
CD3 antibodies and IL-2 to the culture medium. Starting from a small subset (left dot plot 
graph), CD3+CD56+ cells progressively expand to comprise a large percentage of the cell 
population present at the end of culture period (right dot plot graph). 
To identify the  subpopulation giving origin to CIK cells, the CD3+CD56- T cell and CD3-CD56+ NK cell 
subsets present in culture at the beginning of expansion were purified from PBMCs, and stimulated 
with IFN-γ, OKT3 and IL-2. Under these conditions, T cells acquired the expression of CD56, while NK 
cells did not show phenotypic changes20. Similar experiments were performed sorting CD3+CD56+ 
cells, demonstrating that this subset is able to maintain its phenotype but does not further expand 
in respect to the total cell number. Thus, CD3+CD56+ CIK cells derive from T cells present in PBMCs, 
and not from NK cells or from the few CD3+CD56+ cells present in the starting culture21.  
In vitro-generated CD3+CD56+ CIK cells are mostly CD8+, and express the αβ and γδ TCR in 
proportion similar to that found in the peripheral blood T cells. CIK cells are also characterized by 
high levels of Natural-killer group 2 member D (NKG2D) and CD1121. The antitumor activity of CIK 
cells is associated with the CD3+CD56+ subset20, which exert a potent cytotoxicity only against both 
hematological and solid malignancies without prior exposure or priming, but not against normal 
tissues and hematopoietic precursors21,22. Functional assays using blocking antibodies against CD3, 
CD8, CD56, TCR α/β, and MHC class I and II molecules failed to inhibit the cytotoxic activity, 
demonstrating that CIK cells recognize target cells by TCR- and MHC-independent mechanisms; on 
the other hand, a significant inhibition was obtained blocking CD11 and ICAM-1, suggesting that 
cell-to-cell contact is strongly required for cytolysis23,24.  
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The molecule that plays the most important role in tumor recognition is likely NKG2D, a member of 
the c-type lectin-activating receptor family that is expressed on all NK cells. It recognizes at least 6 
counter ligands, which include the MHC-class I-like molecules, MICA and MICB, and members of the 
UL-16 protein binding family (ULBP1-4), named for the ability of some members to bind the UL-16 
protein of cytomegalovirus25. Interestingly, the ligands for NKG2D appear to have an expression 
pattern relatively restricted to malignant tissues26,27. NKG2D has a significant role in the triggering 
of IL-2-activated NK cells inducing calcium flux, cytokine release, and cytotoxicity28. NKG2D 
expression is upregulated in CIK cells by the presence of IFN-γ, high-dose IL-2, and TCR-crosslinking 
with OKT3 Ab. Studies with anti-NKG2D blocking antibodies, small interfering RNA, or redirected 
cytolysis, indicated that most CIK cell cytotoxicity is exerted through the NKG2D rather than TCR 
engagement25,29. While NKG2D mediates the interaction between CIK cells and tumor targets, the 
final cytotoxic mechanism is perforin- and granzyme-mediated. In fact, CIK cells generated from 
perforin-knockout mice are completely lacking their tumor killing ability in in vitro experiments. 
Similarly, the adoptive infusion of CIK cells generated from FASL-deficient or wild-type mice, 
protected the animals from a lethal dose of lymphoma cells, while no tumor protection was 
observed following the infusion of perforin-deficient CIK cells30.  
When tested as a bulk population, CIK cells have been reported to maintain an alloreactive 
proliferation similar to that observed with fresh lymphocytes. However, when the CD3+CD56- T cell 
and CD3+CD56+ CIK cell subsets were tested separately, it became evident that most of the 
observed proliferation was due to T cells, while CIK cells showed only minimal alloreactivity 
capacity22. One possible explanation for the low graft-versus-host disease (GVHD) incidence is the 
abundant production of IFN-γ, spontaneously occurring in expanded CIK cells, and known to be 
protective against GVHD31,32. CIK cells generated from IFN-γ-knockout mice, rapidly induced lethal 
GVHD when infused across MHC-barriers, in contrast to the wild-type counterpart that confirmed a 
minimal GVHD potential32,33.  
With the availability of bioluminescence imaging (BLI) technologies, in vivo functional activities of 
CIK cells have been visualized in a real-time fashion in mice inoculated with bioluminescent gene-
transfected tumor cells and treated with CIK cells for cellular immunotherapy. Using the same 
strategy, CIK cells were transfected with the luciferase genes (luc+) to visualize their in vivo 
trafficking by BLI. Following intravenous injection in tumor-bearing mice, luc+ CIK cells first reached 
the lungs within 30 minutes, to thereafter generally distribute to other sites of the body within the 
next 16 hours. By 72 hours, a population of the labeled CIK cell infiltrated the tumor and remained 
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detectable by BLI at this site for an additional period of 9 days with resultant tumor regression34. 
CIK cells retain NKG2D-mediaded antitumor activity in vivo, as their killing activity was inhibited by 
the in vivo administration of NKG2D blocking antibodies33.  
Several clinical trials have assessed the feasibility of CIK cell application in immunotherapy protocols 
(Table 1). CIK cells can be successfully generated from healthy donors, as well as from patients 
treated with chemotherapy for various malignancies35. Feasibility for large-scale expansion was also 
reported for cord blood, and even from washout of leftover mononuclear cells from cord blood unit 
bags19. Different clinical trials have been carried out in patients affected by different malignancies36, 
in both the allogeneic and autologous settings, in several cases getting significant therapeutic 
success with complete responses, stabilization of disease and prolonged survival. Noteworthy, the 
most common side effects, such as fever, headache and fatigue, were not severe and did not last 
beyond 24 h, being easily controllable with symptomatic treatments. Mild GVHD occurred in some 
patients but was responsive to corticosteroids36. 
Table 1 (see next page): Therapeutic effects of CIK cell immunotherapy in phase I/II clinical 
trials sorted by tumor entity. Therapeutic success was defined as “High” if it was observed 
(i) complete remission (CR) in more than 10 % and/or (ii) significantly prolonged overall 
survival in more than 20 % of patients who underwent CIK cell treatment as compared with 
control group. The therapeutic success was defined as “Very high” in tumor entities in which 
we obtained data about (i) CR in more than 20 % of patients and/or (ii) significantly 
prolonged overall survival in more than 40 % of patients as compared with control group. All 
other clinical responses as partial remission, minor remission, stable disease and progressive 
disease were not defined as therapeutic success. CR: complete remissions in patients treated 
with CIK cells; PR: partial remissions in patients treated with CIK cells; OS: significantly 
prolonged overall survival in patients treated with CIK cells as compared with control group 
(from 36). 
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Therapeutic monoclonal antibodies and Antibody-Dependent Cell-mediated 
Cytotoxicity (ADCC) 
In the last twenty years, the use of monoclonal antibodies (mAbs) to treat patients with 
hematological and solid tumors has achieved considerable success. To date, more than 20 
antibodies have received FDA approval for the treatment of various types of tumors, and even 
more molecules are under evaluation in different stages of clinical trials37. The therapeutic mAbs 
target and attack tumor cells through various mechanisms of action, including the inhibition of  cell 
proliferation, the blocking of immune cell inhibitory signals, and the recruitment of immune cells to 
kill targets through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC)37. Numerous preclinical 
and clinical studies demonstrated a critical role for Fc receptors suggesting that ADCC may be a 
major mechanism of action of several mAbs used in cancer immunotherapy (Table 2), including 
trastuzumab and cetuximab38.  
Trastuzumab is a humanized IgG1 antibody specific for human epidermal growth factor receptor 2 
(Her2)39, while cetuximab is a epidermal growth factor receptor (EGFR)-specific chimeric IgG1 
antibody40. Both Her2 and EGFR are members of the ErbB receptor family of transmembrane 
tyrosine kinases, which are physiologically expressed on epithelial cells, but when overexpressed, 
are involved in tumorigenesis. Her2 is overexpressed in some adenocarcinomas of the lung, ovary, 
prostate and the gastrointestinal tract41, while EGFR can be found in metastatic colorectal cancer, 
metastatic non-small cell lung cancer, and head and neck cancer42. The Fab region of both 
trastuzumab and cetuximab binds tumor receptors, blocking the interaction with ligand, inhibiting 
receptor dimerization and cell growth signals transduction, with a final downregulation and 
internalization43. These two antibodies, bearing a human IgG1 Fc, are able to efficiently recruit 
immune cells to carry out the antibody indirect mechanisms of action, inducing ADCC (Figure 2). 
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Table 2: Representative tumor-antigen targeting monoclonal antibodies an 
immunocytokines functioning through ADCC. The table is a selected (not complete) list of 
therapeutic mAbs that are capable of inducing ADCC (from 44). 
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Figure 2: Mechanism of action of trastuzumab and cetuximab. Binding of trastuzumab to 
Her2 inhibits receptor dimerization and cell growth signals transduction (left), leading to 
downregulation through internalization (middle). Trastuzumab can recruit Fc-expressing 
immune effector cells, activating ADCC and leading to tumor cell killing (right). Cetuximab 
exerts its therapeutic effect using similar mechanisms upon binding EGFR (adapted from 39). 
Indeed, Fc region of mAbs bind to the extracellular portion of Fcγ receptors (FcγRs), which are 
expressed with different patterns by various cell types of the immune system, namely monocytes, 
macrophages, neutrophils and NK cells. 
FcγRs can be divided in activating and inhibitory receptors. Inhibitory receptors are endowed with 
an immunoreceptor tyrosine-based inhibitory motif (ITIM) in their intracytoplasmatic domain45; the 
major inhibitory receptor is CD32a (FcgRIIa). By contrast, activating receptors possess a 
cytoplasmatic immunoreceptor tyrosine-based activation motif (ITAM), which can be either 
encoded directly or gained by association with a common ITAM γ-chain45. CD64a (FcγRIa) is the 
activating receptor expressed by macrophages, dendritic cells, neutrophils and eosinophils, and 
binds antibody Fc region with high affinity. CD16a  (FcγRIIIa) is expressed  by  NK  cells, dendritic  
cells,  macrophages  and  mast  cells,  binds antibody Fc region with low affinity and  is  required  for  
ADCC46.    
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The binding of antibodies to tumor cells enables their recognition and destruction by FcγRs-
expressing immune effectors47. Cross-linking of the FcγRs extracellular domain results in the 
tyrosine phosphorylation of the ITAM, and activation of signal transduction pathways that lead to 
NK cell degranulation, release of perforin and granzyme B, cytokine secretion, and finally tumor cell 
lysis48. Thus, IgG1 mAbs are able to engage the immune system through the interaction of the Fc 
domain with FcγRs, which thus act as a connection between humoral and cellular immune 
response. 
Numerous preclinical models and clinical studies strongly support the role of FcγR-mediated 
effector functions in mAbs cancer therapy, and the correlation between mAb binding affinity to 
FcγR and efficacy. Indeed, studies involving breast carcinoma xenograft models demonstrated that 
the anti-tumor response to trastuzumab was reduced in KO mice not expressing activating FcR; 
additionally, the use of antibodies engineered to disrupt Fc binding to FcγR indicated the 
fundamental role of Fc interaction with FcR for mAbs to exert efficacy49. Moreover, it has been 
reported that certain FcγR polymorphism can determine the clinical efficacy of trastuzumab50 and 
cetuximab51. For example, CD16 is characterized by the valine (V)/phenylalanine (F) polymorphism 
at position 158, which determine a high (V158) or low (F158) affinity for the Fc, with a 
corresponding higher or lower induction of ADCC activity, respectively52. Patients bearing CD16-
158V/V genotype showed improved response rates and prolonged overall survival when treated 
with trastuzumab and cetuximab, supporting the hypothesis that FcγR-mediated ADCC plays an 
important role in clinical effect of these mAbs50,51. Taken together, these studies indicate that the 
recognition of Fc receptor, and thus the triggering of ADCC, is an essential component of in vivo 
anti-tumor efficacy of trastuzumab and cetuximab.  
Optimization of antibody interaction with CD16a (FcγRIIIa)  
Since ADCC is suggested as a key contributor to the in vivo antitumor activity of many mAb 
therapies, increasing their binding affinity to FcγRs and thus enhancing their ability to mediate 
ADCC, is expected to markedly improve clinical efficacy of therapeutic antibodies. The interaction 
between CD16 and mAbs has been optimized by engineering the Fc region of mAbs, either through 
amino acid substitutions in the Fc portion or modification of Fc-linked glycosylation53.  
The nature of oligosaccharides attached to the Asn297 of CH2 domain of the IgG heavy chains, is 
crucial for FcRs binding (Figure 3). The removal of a fucose at this particular site induces 
conformational changes that selectively increase the binding affinity for CD16, with consequent 
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enhancement of ADCC efficacy54,55. A rationale for increased affinity may be the reduction or 
absence of steric inhibition at the receptor-ligand interface, exposing regions that are otherwise not 
accessible to interaction with CD16. On the other hand, non-glycosylated CD16 has the same 
binding affinity for fucosylated as well as non-fucosylated IgG Fc56, supporting the finding that also 
carbohydrate interactions of Fc and FcR are important for enhanced binding57. Fucose-lacking 
antibodies are produced using Lec13 cell line, a variant of the Chinese hamster ovary cell line (CHO), 
which is unable to add the fucose but provides IgG with a glycosylation pattern that is otherwise 
similar to that found in normal CHO cell lines and in human serum55,58. An alternative approach to 
modify antibodies fucosylation is the overexpression or knockout of key enzymes involved in the 
production of CH2-attached oligosaccharides59. Clinical trials are already evaluating non-fucosylated 
antibodies for therapy60,61, such as the defucosylated anti-CCR4 humanized monoclonal antibody 
that received the first approval in Japan62.  
Protein-engineered antibodies are obtained by the substitution of specific amino acids in the 
protein backbone, and in particular in the hinge or CH2 regions of antibodies. Several antibody 
variants showed a significantly enhanced binding affinity for CD16 and effector functions63,64. By 
combining single-amino acid variants, double and triple variants can be obtained. In particular, 
antibodies harboring the S239D-I332E double amino acid substitution were shown to trigger 
stronger NK cell-mediated ADCC59,63. 
Introducing modifications at both the fucose level and the amino acid sequence, combined glyco- 
and protein-engineered antibodies were obtained. Depending on the modification used in 
combined approaches, different effects on immune cells were acquired, including the enhancement 
of CD16 binding, the triggering of NK-cell mediated ADCC, or the selective binding to different 
FcγRs55,65. Taken together, these studies demonstrated that the modification of antibody Fc is a 
promising approach to improve ADCC activity of therapeutic antibodies, producing molecules 
endowed with a unique FcγR binding and selectivity profile, and resulting in a tailored spectra of 
effector mechanisms. The full length Fc-engineered antibodies used in this thesis project  were 
generated based on the V-regions of trastuzumab and the constant regions of a IgG1 antibody, 
either in the wild type format or in a modified form bearing two amino acid substitutions to 
enhance binding to CD16 (S239D/I332E, named V90 variant)63. The production of these protein-
engineered molecules in Lec13 or in wild type CHO cells allowed to obtain antibodies with different 
levels of fucosylation65 (Figure 4). Similar antibodies were derived from rituximab, which targets 
CD20 instead of Her2, and were used as controls. 
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Figure 3: Antibody structure and sites for engineering. IgG antibodies are composed by a 
Fab region, which mediates antigen binding, and a Fc region, which interacts with FcγRs 
expressed by effector cells and triggers ADCC. Effector functions require the presence of a 
glycan moiety (dark blue) in the Fc-region, and are crucially influenced by its structure. The 
N-linked glycan that is attached to the conserved asparagine (Asn) residue at position 297 
comprises a core structure of N-acetylglucosamine and mannose, plus additional 
carbohydrate residues that can vary, including fucose, galactose, sialic acid and bisecting N-
acetylglucosamine (adapted from 66). 
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Figure 4: Schematic representation of engineered antibodies. Amino acid substitutions 
were introduced in the protein backbone of trastuzumab. Variants lacking Fc fucosylation 
were produced in Lec13 cells, while variants containing fucose in the Fc bound 
carbohydrates were expressed in CHO cells.  
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Bispecific antibodies and recombinant immunoligands 
Besides Fc engineering, other strategies to enhance effector cell recruitment and activation are 
available. Advances in antibody engineering have generated novel antibody constructs by 
assembling different parts of native antibodies, and thus obtaining molecules that have two, three 
or even four binding sites, which simultaneously can target different epitopes on tumor as well as 
on immune effector cells (Figure 5)66.  
 
Figure 5: Representative antibody formats. The modular domain architecture of 
immunoglobulins has been exploited to create a growing range of alternative antibody 
formats. The building block that is most frequently used to create novel antibody formats is 
the single-chain variable (V)-domain antibody fragment (scFv), which comprises V domains 
from the heavy and light chain (VH and VL domain), joined by a peptide linker (adapted from 
66). 
Different formats of genetically-engineered bispecific antibody-derivatives have been designed, for 
example diabodies, tribodies, minibodies and single chain diabodies66,67. Several of these non-
conventional antibodies have been shown to have equivalent or superior potency as compared to 
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their IgG counterparts, and some are being evaluated in clinical trials68. Bispecific antibodies (BsAb) 
combine two binding specificities, one directed against a tumor-associated antigen, and the other 
directed against a trigger molecule on effector cells. Thereby, these antibody-variants with 
immunomodulatory functions are able to activate and enhance effector cells cytotoxicity, by 
binding to cytotoxic trigger molecules, such as CD3 and CD1669. Thus, they efficiently recruit 
cytotoxic effector cells to the tumor site and activate them to mediate the elimination of the cancer 
cells via redirected lysis68. The engagement of CD3 allows the triggering of CD3+ T cells, which 
cannot be directly recruited by the conventional IgG antibodies, as they usually do not express Fc 
receptors. An example of a bispecific antibody already evaluated in clinical trials is Blinatumomab, 
which is directed against both CD3 and CD19, a tumor-associated antigen expressed by B cell 
malignancies. It proved to have high efficacy in tumor eradication and improved patients survival, 
thus obtaining the FDA approval for the treatment of refractory acute lymphoblastic leukemia68. 
Recombinant immunoligands are bispecific fusion proteins consisting of a single-chain fragment 
variable (scFv) specific for a tumor-associated antigen fused to the C-terminus of a ligand for an 
activating receptor, such as ULBP-2 or B7 homolog 6 (B7-H6), which are ligands of the NKG2D and 
NKp30 activating NK cell receptors, respectively (Figure 6). In a recent report, Kellner et al. 
demonstrated that similar immunoligands bearing the scFv of the 7D8 anti-CD20 antibody fused to 
NKG2D and NKp30 ligands (designated as ULBP2:7D8 and B7-H6:7D8), were able to bind to target 
cells and to mimic an induced-self phenotype, which efficiently triggered NK cells to kill lymphoma 
and leukemia cells70,71. Indeed, by mimicking an induced-self phenotype, such recombinant 
immunoligands convey  a danger signal, trigger effector cell cytotoxicity and enhance ADCC72. 
Compared to mAbs, the reduced size favors tumor penetration, and the lack of the Fc domain 
avoids retention on non-activating Fc receptors or on Fc receptors expressed by non-cytotoxic 
cells72.  
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Figure 6: Enhancing CIK cell cytotoxicity by recombinant immunoligands. (A) Tumor-
directed recombinant ligands are bispecific fusion proteins consisting of a scFv specific for a 
tumor-associated antigen, fused to the C-terminus of a ligand (e.g., ULBP2) for an activating 
NK cell receptor (e.g., NKG2D). (B) Binding a tumor-associated Ag via their scFv moiety, 
recombinant immunoligands mimick an “induced-self” phenotype, thereby facilitating the 
recognition of cancer cells by NK cells and inducing NK cell-mediated cytotoxic functions 
(adapted from 72). 
For the purposes of this study, we used a bispecific antibody in the tandem scFv format, which 
monovalently binds and targets CD3 and Her2, respectively73. This molecule consists of a CD3-
directed scFv-fragment that is C-terminally fused to a Her2-specific scFv (Figure 7 A). A similar 
molecule targeting CD20, instead of Her2, served as a control. The resulting fusion proteins were 
designated as Her2xCD3 and CD20xCD3, respectively. 
To generate recombinant immunoligands, the extracellular domains of B7-H6 and ULBP-2 were 
genetically fused to a Her2-specific scFv derived from the humanized antibody humAb4D5-874, and 
endowed with a 6 x His-tag to allow purification. The resulting fusion proteins were designated as 
B7H6xHer2 and ULBP2xHer2, respectively (Figure 7 B).  
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Figure 7: Schematic representation of bispecific antibodies. (A) CD3xHer2 molecule is 
composed by two scFv targeting CD3 and Her2, respectively. (B) The extracellular domain 
(ECD) of B7-H6 is genetically fused to a Her2-specific scFv. CMV indicates the 
cytomegalovirus immediate early promoter. 
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AIM OF THE STUDY  
Adoptive cell immunotherapy is a very promising approach for the treatment of cancer 
patients. While several approaches have proven highly efficient at preclinical level and 
encouraging results have been collected in some clinical settings, numerous difficulties still limit 
the effective translation of ACT in clinics. In most cases, the expansion of large amounts of 
antitumor immune effectors, their persistence in vivo, selective tumor killing, restriction to 
specific human MHC alleles and safety, are still crucial and open issues. Very promising results 
have been provided from studies on CIK cells, as they present unique biological and functional 
characteristics that may favorably affect their clinical translation. 
The aim of this study was to characterize CIK cells more thoroughly at both a phenotypical and 
a functional level. In particular, our attention focused on the expression of CD16 and its 
relevance as a potential inducer of ADCC by CIK cells when combined with clinical-grade 
antibodies. Moreover, different strategies for the improvement of CIK cell antitumor activity 
were assessed, including the combination with engineered antibodies and recombinant 
immunoligands targeting other activating receptors different from CD16. 
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MATERIALS AND METHODS 
Generation and characterization of CIK cells 
CIK cells were obtained from healthy donors as previously reported by other groups18–20. Peripheral 
blood mononuclear cells (PBMCs) were isolated from buffy coats by means of Ficoll-Paque PLUS (GE 
Healthcare) density gradient centrifugation. The monocytes were depleted by adhesion to tissue 
culture flask for 90 minutes. The non-adherent cells were resuspended and cultured at a density of 
1 to 2x106 cells/ml in complete medium consisting of RPMI 1640 (Euroclone), 10% heat-inactivated 
FBS (Gibco), 1% Ultraglutamine, 1% Hepes buffer, 1% penicillin/streptomycin (Lonza) at 37°C, 5% 
CO2. At day 0, medium was supplemented with rhIFN-γ (PeproTech) at 1000 U/ml. After 24 hours of 
incubation, anti-CD3 mAb (OKT-3, Ortho Biotech Inc) at 50 ng/ml and rhIL-2 (Proleukin, Novartis) at 
300 IU/ml were added to the culture medium. Every 2-3 days medium was replenished by adding 
fresh rhIL-2 at 450 IU/ml. CIK cells phenotype was analysed using multi-colour flow cytometry. 
Briefly, cells were harvested between day 7 and 28 and counted with a Nebauer chamber; 0.5x106 
cells were washed with staining buffer (PBS 1% FBS) and centrifuged to obtain a pellet. Staining was 
performed in a final volume of 50 µl, for 30 minutes at 4°C, using the following antibodies: CD3-
BV510 (clone UCHT1), CD8-BV421 (clone RPA-T8), CD4-APC-H7 (clone RPA-T4), CD28-PE-CyTM7 
(clone CD28.2), TCRα/β-FITC (clone T10B9.1A-31), TCRγ/δ-BV421 (clone B1), CD11a-FITC (clone 
G43-25B) from BD Bioscience; CD56-PE (clone HCD56), NKG2D-APC (clone 1D11), CD16a-FITC (clone 
3G8), NKp30-APC (clone P30-15), NKp44-APC (clone P44-8) from BioLegend; NKp46-APC (clone 9E2) 
from Miltenyi Biotec. For CD16 staining, cells were pre-incubated with 2.5 µg/106 cells of Human BD 
Fc Block (BD Pharmingen) to avoid non-specific Fc Receptor-mediated antibody binding. Flow 
cytometry analysis was performed either on FACScalibur or LSRII, using CellQuest software (BD 
Bioscience). Data analyses were performed using FlowJo software (Treestar). 
Depletion of NK cells  
Where reported, NK cells were removed from bulk cultures by immunomagnetic depletion. CIK cells 
were harvested at day 14 to 21, and stained with an APC-conjugated anti-NKp46 antibody (Miltenyi 
Biotec) in a final volume of 200 µl, for 20 minutes at 4°C. Cells were then washed, mixed with anti-
APC microbeads (Miltenyi Biotec), and incubated for 15 minutes on ice. MS MACS Columns and 
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MACS Separator from Miltenyi Biotec were used according to the manufacturer instructions. 
Unlabeled cell fraction, containing NKp46- CIK cells, and bead-coated cells, containing NKp46+ NK 
cells, were collected separately, washed with PBS and stained with fluorochrome-conjugated 
antibodies to verify purity of fractions. 
Cell lines and cultures 
The following cell lines were used in this study: K562 human erythroleukemia cells; Raji human B-
cell lymphoma cells; HCT-15, HT29 and LoVo human colorectal adenocarcinoma cells; PC-3 human 
prostate cancer cells; Panc human pancreatic carcinoma cells; MKN-45 human gastric cancer cells; 
H2452 and H28 human mesothelioma cells; SKOV-3, IGROV-1, A2780 and OVCAR-3 human ovarian 
carcinoma cells; MDA-MB-231 and MDA-MB-468, human breast adenocarcinoma cells; pdOVCA37, 
pdOVCA39, pdOVCA46, pdOVCA49bis, pdOVCA52, pdOVCA57, pdOVCA66, primary ovarian cancer, 
which were obtained from ascitic fluids of ovarian cancer patients and were kindly donated from 
Dr. Indraccolo. Cells were maintained in DMEM (Panc, MDA-MB-231 and MDA-MB-468) or RPMI 
1640 (all the other cell lines) medium (Euroclone) supplemented with 10% heat-inactivated FBS 
(Gibco), 1% Ultraglutamine, 1% Hepes buffer, 1% penicillin/streptomycin (all Lonza). For HCT-15, 
HT29, LoVo, H2452, H28, SKOV-3, IGROV-1, A2780 and OVCAR-3 cell lines the RPMI medium was 
additionally supplemented with 1% Sodium pyruvate (Lonza). All cell lines were grown in 25, 75 or 
175 cm2 flasks (Falcon, Becton Dickinson) and under standard conditions (5% CO2 and 37 °C). All cell 
lines were authenticated by STR sequences analysis. 
Assessment of HER2 and EGFR expression  
The expression of Her2 and EGFR was assessed on cell lines by flow cytometry using as primary 
antibodies the humanized anti-Her2 monoclonal IgG1 antibody trastuzumab (Roche) and the 
chimeric mouse-human anti-EGFR monoclonal IgG1 antibody cetuximab (MerckSerono), 
respectively, and a PE-conjugated anti-IgG1 antibody (Miltenyi Biotec) as secondary antibody. 
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Cytotoxicity assays 
Cytotoxic activity of CIK cells was assessed using a standard 4-hours 51Cr-release assay. A total of 106 
target cells were labelled with 100 µCi 51Cr for 1 hour at 37°C, washed twice with culture medium. 
Depending on the experiment, target cells were incubated for 30 min with 10 µg of trastuzumab or 
cetuximab, or scaling concentrations of engineered antibodies or bispecific immunoligands, ranging 
from 10 µg/ml to 3.2 ng/ml. For blocking experiments, effector cells were incubated for 30 min with 
10 µg anti-CD16 blocking antibody. Target and effector cells were then plated at the indicated E/T 
ratio in a 96-well U-bottom plate in a total volume of 200 µl. After a 4-h incubation at 37°C, 30 µl 
supernatant was removed from each well and transferred on a scintillation plate (Perkin Elmer), 
and measured using a Top Count gamma counter (Perkin Elmer). Each test was performed in 
triplicate. The results are expressed as the percentage of lysis, which is calculated as follows: % 
Specific Lysis = (experimental release – spontaneous release)/(maximal release–spontaneous 
release) x 100. Spontaneous and maximal release were obtained by incubating target cells in 
medium alone or in PBS 2% SDS, respectively.  
Trasduction of tumor cells with luciferase gene 
To visualize tumor cells in vivo by bioluminescence imaging, SKOV-3 and IGROV-1 cells were 
transduced with the Luciferase enzyme gene, using a lentiviral vector coding for luciferase (LV-LUX)75 
(Figure 8). Cells were harvested and resuspended in 1 ml complete medium with concentrated LV-
LUX. Cells were incubated O.N. at 37°C in the presence of the virus, then the supernatant containing 
the virions was discarded and fresh medium was added. Seventy-two hours after infection, cells 
were tested for the luciferase activity. The cells were collected, resuspended in 50 µL PBS and plated 
in a 96-well black plate (Nunc). 50 µL of D-Luciferin (0.3 mg/ml, Caliper) was then added  and the 
photons emitted by the positive Lux cells  were read by using IVIS Lumina II (Caliper). 
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Figure 8: LV-LUX vector used for tumor cell transduction. The Fluc gene is driven by a 
cytomegalovirus (CMV) promoter and followed by the truncated nerve growth factor 
(tNGFR) gene, separated by an internal ribosomal entry site (IRES). Tumor cells were 
transduced and assessed for luciferase expression by BLI. 
In vivo studies 
On day 0, female NOD/SCID common γ chain knockout (NSG, Charles River) mice at 6 weeks of age 
were injected intraperitoneally with tumor cells (106 SKOV-3 or IGROV-1 cells), and randomly 
assigned to four experimental groups. The first group received the combined treatment of 1 mg 
trastuzumab or 1.5 mg cetuximab on day 3, 6, 9 with 107 CIK cells on day 4, 7, 10 after tumor 
injection. The other three experimental groups were used as control: mice received PBS or only the 
mAbs or only CIK cells, at the same doses and on the same days of the combined treatment. Tumor 
growth was monitored weekly by BLI under isoflurane gas anesthesia. Ten to fifteen min before 
imaging, each mouse received a single i.p. injection of 150 mg/kg of D-luciferin (Xenogen/Caliper) in 
PBS and was positioned properly to obtain ventral images within the imaging chamber of IVIS 
Lumina II (Xenogen/Caliper). 
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Figure 9: Schedule of mice treatment. On day 0, mice received intraperitoneally 1x106 
SKOV-3 or IGROV-1 cells. Depending on the experimental group, treatments consisted of a 
combination of 1 mg trastuzumab or 1.5 mg cetuximab on day 3, 6, 9 and 1x107 CIK cells on 
day 4, 7, 10, or mAbs or CIK cells only at the same doses and on the same days of the 
combined treatment. The untreated group received three injections of PBS. Tumor growth 
was monitored weekly by BLI and mice survival was recorded. 
Production and purification of antibody derivatives 
Recombinant immunoligands were transiently expressed in Lenti-X 293 T cells (Takara Bio Europe / 
Clontech), which were maintained in DMEM supplemented with 10% FCS, 100 U/ml penicillin and 
100 µg/ml streptomycin. For this purpose, 10 µg of the respective expression vectors were 
transfected using the calcium phosphate procedure including 5mM chloroquine. After 9 h, the 
transfection medium was replaced by fresh culture medium. Tissue culture supernatants were 
collected twice in a week. The bispecific antibody was captured on CaptureSelect™ IgG-CH1 affinity 
matrix (Life Technologies). The 6 x His-tagged immunoligands were dialyzed at 4°C in a buffer 
containing 50 mmol/l NaH2PO4, 300 mmol/l NaCl, 10 mmol/l imidazole, pH 8.0, and then purified by 
affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen). The 
proteins were then extensively dialysed against phosphate-buffered saline (PBS; Invitrogen) and 
stored at 4°C until use. 
Antibody derivatives were analysed by SDS-PAGE under reducing and non-reducing conditions, 
according to standard procedures. Purity and concentrations of the purified proteins were 
estimated against a standard curve of BSA by Coomassie staining (colloidal Coomassie brilliant blue 
G250 solution (Carl Roth GmbH)) or determined by quantitative capillary electrophoresis using an 
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Experion Pro260 Automated Electrophoresis System (Bio-Rad), according to the manufacturer’s 
instructions. 
Statistics 
Results were analyzed for statistical significance by using paired or unpaired Student t test, as 
appropriate (***P<0.001, **P<0.01, *P<.05). Mice survival was compared using log-rank survival 
statistics. Histograms represent mean values ± standard deviation. In scatter-plot graphs, symbols 
indicate different samples or assays, and horizontal bars represent means ± standard deviation. 
Statistical analysis was performed using GraphPad Prism 4.0 software. 
Study approval 
Anonymized human buffy coats were obtained from the Blood Bank of Padova Hospital, and donors 
provided their written informed consents to participate in this study. Procedures involving animals 
and their care were in conformity with institutional guidelines that comply with national and 
international laws and policies (D.L. 26/2014 and subsequent implementing circulars), and the 
experimental protocol (Autorizzazione n. 1143/2015-PR) was approved by the Italian Ministry of 
Health. 
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RESULTS 
Characterization of CIK cell phenotype and antitumor activity 
CIK cells were obtained from PBMCs of healthy donors by the timed addition of IFNγ, anti-CD3 
(OKT3) antibody and IL-2, as previously reported18,20 and described in the Material and Methods 
section. After 3 weeks of expansion, the resulting effector cell population comprised about 40% of 
cells co-expressing CD3 and CD56, while NK cells not only did not expand under this culture 
conditions, but progressively declined (Figure 10 A). Multi-colour cytometry analysis of the 
CD3+CD56+ subpopulation was carried out throughout the culture period to evaluate the expression 
of different markers. Results essentially confirmed the already reported phenotype21,23–25 (Figure 
10). In particular, the CD8 component of CD3+CD56+ CIK cells expanded reaching 82.7±4.2% of 
positivity at day 28, whereas the CD4 subset progressively decreased to 8.9±1.0%. A similar trend 
was observed for the TCR-expressing subpopulation: TCRα/β+ CIK cells increased during culture from 
63.3±19.5% to 83.7±7.9%; in contrast, TCRγ/δ+ CD3+CD56+ cells decreased from 29.2±17.7% to 
11.9±4.1%. At the end of culture almost 100% of cells expressed NKG2D (96.1±2.0%), while both 
CD28 (22.8±12.9%) and CD11 (94.2±5.0%) did not underwent substantial modifications (Figure 10 B).  
 
Figure 10: Phenotypic characterization of CIK cells. CIK cells were generated in vitro and 
analyzed for their phenotype by flow cytometry throughout the culture period. In the figure, 
histograms refer to three distinct time points, namely day 0 (black), day 14 (grey) and day 28 
(white). (A) Percentage of CD3+CD56+ CIK cells and CD3-CD56+ NK cells in the bulk cultures 
at the reported time points. (B) Expression of different cell surface markers on CD3+CD56+ 
cells at the reported time points, as assessed by flow cytometry analysis. Results show the 
mean expression ± SD of 5 to 15 independent experiments performed on PBMCs and related 
cultures from distinct donors.  
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Next, the functional activity of CIK cells was evaluated against various tumor cells. CIK cells were 
assessed for lytic activity between day 14 and 21 of the culture, by a standard 4-hour 51Cr-release 
assay using a broad range of tumor cell lines of different histotypes as target cells. Overall, CIK cells 
showed a dose-dependent cytotoxicity against all tumor cell lines tested, which however 
demonstrated a variable susceptibility to killing (Figure 11 and Figure 12). K562 cells were used as a 
positive control, as they have been already widely described as susceptible to NK-like killing20,76. 
Indeed and as expected, CIK cells were highly cytotoxic against K562 cells (58.1±11.2% at an E/T 
ratio of 25:1; Figure 11). A high antitumor activity against colorectal cancer cells was also observed, 
with a specific lysis of HCT-15, HT29 and LoVo cells of 63.0±15.8%, 26.8±13.6% and 32.5±12.0%, 
respectively, at an E/T ratio of 25:1. CIK cells also killed effectively prostate cancer cells (PC-3), with 
a specific lysis of 40.0±12.6% at the higher E/T ratio tested. The MKN-45 gastric cancer cells and the 
H2452 mesothelioma cells were less susceptible to killing, with a specific lysis of 18.5±12.0% and 
14.7±7.4%, respectively. Breast cancer cell lines (MDA-MB-231 and MDA-MB-468) showed low 
susceptibility to CIK cell killing, with a specific lysis of 11.1±7.9% and 8.6±4.1%, respectively (Figure 
11). 
 
Figure 11: CIK cell cytotoxicity against different tumor cell lines. CIK cell lytic activity was 
measured between day 14 and 21 of the culture by 51Cr-release assay. Several tumor cell 
lines of different histotypes were tested as target cells at an E/T ratio of 25:1 (black 
columns), 12:1 (white columns) and 6:1 (grey columns). Results show the mean specific lysis 
± SD, while n indicates the number of independent experiments performed.  
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Taking advantage of the availability of a number of primary cell lines derived from ovarian cancer 
patients, we were prompted to assess CIK cell cytotoxicity against both primary samples and in vitro 
stabilized ovarian cancer cell lines. Overall, ovarian carcinoma cells generally showed a good 
susceptibility to CIK-mediated lysis (Figure 12). Among ovarian cancer cell lines, A2780 cells were the 
most susceptible to CIK cell killing, with a specific lysis of 40.3±13.0%, whereas values for IGROV-1 
and OVCAR-3 cells were 29.0±13.5% and 16.4±10.1% (in all cases, at the higher E/T ratio). SKOV-3 
cells were the less sensitive targets, with a cytotoxicity of 8.3±4.2% at the same E/T ratio (Figure 12 
A). When challenged against seven different primary ovarian cancer samples, susceptibility to CIK 
cell cytotoxicity was always detected, albeit at variable levels. The most sensitive cells were 
pdOVCA37, while the less susceptible were pdOVCA66, with a specific lysis of 33.3±15.7% and 
5.3±4.0%, respectively (Figure 12 B). 
 
Figure 12: CIK cell cytotoxicity against ovarian cancer cells. CIK cells were challenged against 
in vitro stabilized ovarian cancer cell lines (left) and primary samples from ovarian cancer 
patients (right). CIK cell lytic activity was measured between day 14 and 21 of the culture by 
51Cr-release assay. Assays were carried out at an E/T ratio of 25:1 (black columns), 12:1 
(white columns) and 6:1 (grey columns). Results show the mean specific lysis ± SD, while n 
indicates the number of independent experiments performed. 
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Assessment of CD16 expression on CIK cells  
To assess CIK cell functionality and perform cytotoxicity assays against such a high number of 
different tumor cell lines, we expanded CIK cells from 97 different healthy donors. This high number 
of samples allowed us to evaluate CIK cell phenotype thoroughly. In particular, our attention 
focused on CD16 expression, because we repeatedly observed results that were discordant from 
those reported in literature. Overall, we studied in depth 60 cultures by flow cytometry using the 
3G8 antibody clone, which had been already used by others21,29, to assess CD16 expression. In our 
large set of samples, a remarkable expression of the CD16 receptor was detected; indeed, a mean of 
16.0±13.3% (range 2.3-54.2%) of CD3+CD56+ cells co-expressed CD16 (Figure 13 A). The CD16-
expressing cells were clearly detectable within the CD3+CD56+ CIK population, as they formed a 
defined and distinct subset in the dot plot graphs (Figure 13 B). CD16 expression in CIK cells was 
donor-dependent and characterized by a marked variability among donors, who were arbitrarily 
classified as “low” (<5%), “intermediate” (>5% and <25%), and “high” (>25%), according to the 
percentage of CD16 expression within their CD3+CD56+ populations (Figure 13 B). Interestingly, the 
fraction of CIK cells expressing the CD16 receptor remained stable during the entire period of 
culture, notwithstanding the enormous expansion of the CD3+CD56+ population. Indeed, 18 samples 
were analysed weekly by flow cytometry, and the expression of CD16 was compared at different 
time points within each sample, but no statistically significant differences were found (Figure 13 C). 
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Figure 13: CD16 expression on CIK cells. CIK cells were analysed for CD3, CD56 and CD16 co-
expression by flow cytometry. (A) CD16 expression was determined on samples obtained 
from different donors (n=60). The figure reports the individual values (grey circles) detected 
in the cultures between the second and third week in vitro. Average and standard deviations 
are also shown. (B) Gating strategy on CD3+CD56+ CIK cells for the evaluation of CD16 
expression on double-positive cells. Bulk cultures were first gated for CD3+ and CD56+ co-
espression to identify the CIK subset (left panel), followed by analysis of CD16 expression 
(right panels). The right panels show triple-positive CIK cells from three representative 
donors who were arbitrarily stratified as having a high (> 25%), intermediate (> 5% and < 
25%) or low (< 5%) expression of CD16. (C) Analysis of the CD3+CD56+CD16+ component at 
different time points of culture showed no statistically significant variations along the entire 
period of in vitro expansion. The donors (n=18) are indicated with different symbols. 
 
Assessment of HER2 and EGFR expression on target cell lines 
Chromium release assays showed the capability of CIK cells to kill a broad range of tumor histotypes. 
The observation that CIK cells express CD16 led us to investigate whether this receptor could 
mediate ADCC in CIK cells, as it occurs in NK cells. In fact, we hypothesized that CIK cell antitumor 
activity could be improved by combination with monoclonal antibodies, such as trastuzumab and 
cetuximab.  
First of all, monoclonal antibodies were used as primary antibodies to evaluate Her2 and EGFR 
expression on target cells lines. K562 and Raji cells, both of hematological origin, were negative for 
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both Her2 and EGFR, as well as negative were A2780, pdOVCA49, pdOVCA57 and pdOVCA66 ovarian 
cancer cells. pdOVCA39 and pdOVCA52 were slightly positive for EGFR, whereas IGROV-1, OVCAR-3, 
pdOVCA37 and pdOVCA46 showed a higher expression level of this receptor. SKOV-3 were the only 
cells expressing both Her2 and EGFR among all cell lines tested. Both MDA-MB-231 and MDA-MB-
468 breast cancer cell lines expressed high levels of EGFR, but resulted negative for Her2 being 
triple-negative tumors (Figure 14). 
 
Figure 14: Her2 and EGFR expression on target cells. Target cells were analyzed for Her2 
and EGFR expression by flow cytometry analysis. Fluorochrome-conjugated secondary 
antibody alone (Ab II) served as negative control. Results are representative of 5 
experiments. 
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Evaluation of CIK cell Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) 
Based on previous results, we decided to study CIK cell cytotoxic activity using two ovarian (SKOV-3 
and IGROV-1) and two breast (MDA-MB-231 and MDA-MB-468) cancer cell lines, as target cells. 
Thus, tumor cells were left untreated or pre-incubated for 30 minutes with 10 µg of trastuzumab or 
cetuximab, and used as targets in a standard chromium release assay.  
Consistently with the receptor expression on target cells, a significant antigen-specific increase of 
cytotoxicity was observed when therapeutic antibodies were added to the assay (Figure 15). Indeed, 
both trastuzumab and cetuximab led to a significant enhancement of cytotoxicity against SKOV-3 
cells, which express both receptors, and increased basal specific lysis (9.1±5.2%) to 35.4±13.8% and 
to 16.1±3.9%, respectively (Figure 15 A). On the other hand, only cetuximab increased CIK cell lytic 
activity toward IGROV-1, MDA-MB-231, and MDA-MB-468, as EGFR only is expressed on these cells; 
in this case, basal specific lysis (35.3±14.2%, 19.7±12.1% and 13.0±12.3%, respectively) increased to 
59.0±7.7%, 45.2±14.4% and 41.3±21.3%, respectively (Figure 15 B-D). Importantly, trastuzumab did 
not increase the killing against Her2 negative target cell lines (Figure 15 B-D), thus suggesting that 
the enhanced cytotoxic activity was indeed mediated by the engagement of CD16 and subsequent 
ADCC.  
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Figure 15: Monoclonal antibodies enhance CIK cells cytotoxicity. CIK cells were challenged 
in a standard cytotoxicity assay against SKOV-3 (A), IGROV-1 (B), MDA-MB-231 (C) and MDA-
MB-468 (D) tumor cell lines. Lytic activity against each cell line was measured using bulk CIK 
cells as effector cells in the absence or presence of 10 µg of trastuzumab or cetuximab. Data 
shown are the percentage of specific lysis at an effector/target ratio of 100:1, with the 
assays carried out when CIK cell cultures were at day 21. The symbols refer to individual CIK 
cell cultures from different donors, and bars indicate mean values ± SD. Data were analyzed 
by Student’s t-test (*** or §§§, P ≤ 0.001; **, ## or §§, P ≤ 0.01; *, # or §, P ≤ 0.05; not 
statistically significant (P > 0.05) if not indicated). 
CD16 blocking assay 
To formally prove that the increase in cytotoxic activity was truly linked to the engagement of CD16 
and the triggering of subsequent ADCC phenomena, CIK cells were pretreated with a mouse anti-
human CD16 blocking antibody to prevent the specific interaction between CD16 and the Fc region 
of therapeutic mAbs. CD16-masking completely abrogated the additional CIK cell lytic activity 
ascribable to the addition of trastuzumab or cetuximab, leading the cytotoxicity to return to the 
basal levels observed with untreated CIK cells (Figure 16). In particular, the cytotoxicity against 
SKOV-3, which was enhanced by the addition of trastuzumab, reduced from 35.4±13.8% to 
19.8±11.2% with the addition of anti-CD16 antibody, this latter value being not significantly different 
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from basal specific lysis (Figure 16 A). Similarly, masking of CD16 led to a specific lysis reduction to 
28.3±15.3%, 24.5±5.8% and 28.3±7.1% for cetuximab-treated IGROV-1, MDA-MB-231, and MDA-
MB-468, respectively, as the interaction between the receptor and mAb is prevented (Figure 16 B-
C). As a control, CIK cells were pretreated with an irrelevant mouse IgG1 isotype antibody, in the 
presence or absence of mAbs, to rule out potential interferences in the tests (Figure 16). In all cases, 
the addition of such control antibody nor reduced the increased activity mediated by trastuzumab 
or cetuximab, nor interfered with basal CIK cell functions.  
 
Figure 16: Blocking CD16 reduces cytotoxicity. CIK cells were challenged in a standard 
cytotoxicity assay against SKOV-3 (A), IGROV-1 (B), MDA-MB-231 (C) and MDA-MB-468 (D) 
tumor cell lines. Lytic activity against each cell line was measured using bulk CIK cells as 
effector cells in the absence or presence of 10 µg of trastuzumab or adding an anti-CD16 
blocking antibody to the corresponding specific mAb, namely trastuzumab in A and 
cetuximab in B, C and D. An isotype antibody served as negative control. Data shown are the 
percentage of specific lysis at an effector/target ratio of 100:1, with the assays carried out 
when CIK cell cultures were at day 21. The symbols refer to individual CIK cell cultures from 
different donors, and bars indicate mean values ± SD. Data were analyzed by Student’s t-test 
(*** or §§§, P ≤ 0.001; **, ## or §§, P ≤ 0.01; *, # or §, P ≤ 0.05; not statistically significant (P 
> 0.05) if not indicated). 
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As different levels of CD16 expression were detected on CIK cells obtained from different donors, 
we wanted to unveil whether cytotoxic activity was dependent on the amount of CD16 present on 
cells. To this aim, we performed cytotoxic assays by using CIK cells presenting different extent of 
CD16 expression. An antibody-mediated increase of the cytotoxic activity could be detected in all 
CIK cultures tested, irrespective of the levels of CD16 expression. Indeed, as shown in Figure 17, the 
cytotoxicity in the presence of the mAbs was statistically comparable between CIK populations with 
different CD16 expression levels, against both ovarian and breast cancer cell lines.  
 
Figure 17: Correlation analysis between CD16 expression and ADCC activity. CIK cells 
samples were arbitrarily stratified as “low” (<5%), “intermediate” (>5% and <25%) and 
“high” (>25%), according to their CD16 expressing levels. The lytic activity of these subsets 
against SKOV-3 (A), MDA-MB-231 (B) and MDA-MB-468 (C) tumor cell lines was then 
measured in a standard cytotoxicity assay, in the presence of the corresponding specific mAb 
(trastuzumab in A, and cetuximab in B and C). The results are reported as the percentage of 
specific lysis at an E/T ratio of 100:1. Each symbol represents a different donor, and bars 
indicate mean values ± SD. Data were analyzed by Student t test. No statistical significant 
differences were found between different groups. 
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Depletion of NK cells and evaluation of killing 
It is well known that CD16 is expressed by CD3-CD56+ NK cells, which also have the ability to kill 
tumor cells by ADCC 77. NK cells were present in PBMCs at the beginning of ex vivo CIK cell expansion 
phase, while their percentage progressively decreased during culture (Figure 1 A). Therefore, to 
verify that the ADCC activity observed was not mainly due to the presence of a residual NK 
subpopulation but rather to the CD3+CD56+CD16+ CIK cells, NK cells were removed from cultures by 
immunomagnetic depletion with a mAb against NKp46 78,79. This receptor is exclusively expressed by 
NK cells, but not by CIK cells21,53,80. Indeed, staining CIK cells with an NKp46-specific antibody, no 
expression was found on CD3+CD56+ cells (Figure 18 A). One example of NK depletion is reported in 
Figure 18 B, in which 10.5% of NK cells were present in bulk population. Immunomagnetic depletion 
allowed to removing almost completely NK cells from the culture, thus obtaining cell populations 
composed only by CD3+CD56+ CIK cells and CD3+CD56- T cells. 
 
Figure 18: NK cell depletion from bulk CIK cell cultures. CIK cells were stained for 
CD3, CD56 and NKp46. (A) Flow cytometry analysis was performed in quadruple 
fluorescence to determine the absence of NKp46 expression on CD3+CD56+ cells. 
(B) NKp46+ NK cells were removed by magnetic beads depletion. The panels show 
one representative experiment out of 5 performed, where flow cytometry analysis 
was carried out before (left) and after (right) NK depletion. 
Thus, bulk and NK-depleted CIK cells were challenged against target cell lines in a standard 51Cr-
release assay, in the presence or absence of the corresponding specific therapeutic mAb. Against all 
target cell lines tested, the cytotoxicity of NK-depleted and bulk CIK cells fully overlapped, both 
alone and in combination with the mAbs (Figure 19). The addition of mAbs to NK-depleted 
populations was still able to produce a significant increase of cytotoxicity. These results demonstrate 
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that the enhanced cytotoxicity induced by mAbs is associated with CD3+CD56+CD16+ subpopulation 
in CIK cell cultures, confirming that CIK cells can perform ADCC by the engagement of CD16. 
 
Figure 19: NK depletion does not affect CIK cell-mediated ADCC. CIK cells were 
challenged in a standard cytotoxicity assay against SKOV-3 (A), IGROV-1 (B), MDA-
MB-231 (C) and MDA-MB-468 (D) tumor cell lines. Lytic activity against each cell 
line was measured using bulk CIK cells or NK-depleted CIK cells (NK depl. CIK) as 
effector cells in the absence or presence of the corresponding mAb, namely 
trastuzumab in A and cetuximab in B, C and D. Data shown are the percentage of 
specific lysis at an effector/target ratio of 100:1, with the assays carried out when 
CIK cell cultures were at day 21. The symbols refer to individual CIK cell cultures 
from different donors, and bars indicate mean values ± SD. Data were analyzed by 
Student’s t-test (*** or §§§, P ≤ 0.001; **, ## or §§, P ≤ 0.01; *, # or §, P ≤ 0.05; not 
statistically significant (P > 0.05) if not indicated). 
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In vivo therapeutic efficacy of CIK cells  
The activity of CIK cells in combination with trastuzumab and cetuximab was evaluated in ovarian 
cancer xenograft models established in NSG mice. To follow tumor growth in vivo by 
bioluminescence imaging, tumor cells were transduced with a lentiviral vector coding for luciferase 
(LV-LUX), and were assessed for luciferase activity using BLI (Figure 20 A). 
On day 0, female mice were injected intraperitoneally with 1x106 SKOV-3-luc or IGROV-1-luc tumor 
cells. Then, animals were randomly assigned to control and experimental groups, and treated i.p. 
with CIK cells in combination or not with the mAbs, as described in the Material and Methods 
section. As shown in Figure 20 B, already three weeks after tumor injection there was a significant 
difference between the experimental groups. Untreated mice showed a very high tumor burden, 
whereas mice treated with CIK cells alone demonstrated a variable response to treatment. The best 
outcomes were achieved in mice receiving mAbs alone and in particular mAbs combined to CIK cells, 
as the tumor growth appeared to be more inhibited. As showed in Kaplan-Meier survival curves in 
Figure 20 C-D, the co-administration of CIK cells and mAbs produced long-term effects and 
significantly increased the survival of both SKOV-3 (Figure 20 C) and IGROV-1 (Figure 20 D) tumor-
bearing mice, as compared to animals receiving CIK cells or mAb alone. In this setting, CIK cell 
monotherapy was not effective in improving the outcome of treated mice; conversely, when 
combined with trastuzumab or cetuximab CIK cells appeared even more efficient than the 
antibodies used alone, confirming the high therapeutic efficacy of the treatment.  
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Figure 20: The in vivo combined approach with mAb and CIK cells improves the 
antitumor activity. (A) Assessment of Luciferase expression by SKOV-3 (left well) 
and IGROV-1 cells (right well) after lentiviral transduction using BLI. (B) Mice were 
injected i.p. with 1x106 transduced tumor cells and were treated with three 
intraperitoneal doses of PBS only (untreated), the corresponding specific mAb only 
(1 mg/mouse of trastuzumab or 1.5 mg/mouse of cetuximab), 107 bulk CIK cells 
only, or both mAbs and CIK cells at the same doses of the other groups. Tumor 
growth was assessed weekly by BLI. The panel shows 3 representative mice for 
each group 3 weeks after tumor injection. (C-D) Mice survival was evaluated by 
Kaplan-Meier analysis. Combination therapy significantly increased survival 
compared to any other treatment, both in SKOV3 (C, P=0.04) and IGROV-1-injected 
mice (D, P=0.03).  
Improvement of CIK cell cytotoxicity: Fc-engineered antibodies 
As we demonstrated the expression of CD16 in CIK cells, and its ability to induce ADCC in vitro and 
to improve the therapeutic efficacy in vivo, we were prompted to investigate whether this function 
could be further improved. To evaluate whether an increased CD16 binding affinity could result in 
enhanced CIK cell cytolytic activity, different Fc-optimized versions of trastuzumab were used in 
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combination with CIK cells. Recombinant proteins were produced, purified by affinity 
chromatography and analyzed by SDS-PAGE with Coomassie staining to determine the protein 
concentration. SKOV-3 cells were used as target cells in the 51Cr-release assays, and pre-incubated 
with the wild-type form of trastuzumab or with the engineered antibodies, in particular the glyco-
engineered Lec13 (trastuzumab Lec13), the protein-engineered V90 (trastuzumab V90) or the both 
glyco- and protein-engineered antibody (trastuzumab Lec13 V90). The presence of the antibodies 
significantly enhanced CIK cell cytotoxicity, inducing a higher cell lysis against target cells as 
compared to the wild type antibody (Figure 21). At lower concentrations (0.0032 µg/ml), the double 
engineered trastuzumab Lec13 V90 triggered ADCC more efficiently in comparison to the other 
engineered antibodies trastuzumab Lec13 and trastuzumab V90. As expected, rituximab, which 
binds the CD20 molecule that is not expressed on SKOV-3 cells, was not able to induce target cell 
killing, either in the wild-type format or in the glyco-engineered form (Figure 21).  
 
Figure 21: CIK cell cytotoxicity is enhanced by engineered antibodies. CIK cells 
were challenged in a standard cytotoxicity assay against SKOV-3 tumor cell line in 
combination with scaling concentrations of the wild-type form of trastuzumab 
(white columns), the glyco-engineered Lec13 (trastuzumab Lec13, striped columns), 
the protein-engineered V90 (trastuzumab V90, grey columns) or the both glyco- 
and protein-engineered antibody (trastuzumab Lec13 V90, black columns). 
Rituximab (dotted columns) and the glyco-engineered rituximab (oblique striped 
columns) served as negative controls. Data shown are the mean percentage ± SD of 
specific lysis at an effector/target ratio of 50:1, and the assays was carried out at 
day 21 of CIK cell cultures. Data were analyzed by one-way ANOVA, but were 
statistically significant (P > 0.05) only when compared to controls (rituximab and 
rituximab Lec13). 
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Improvement of CIK cell cytotoxicity: bispecific antibodies 
To investigate whether CIK cell cytotoxicity could be enhanced through the engagement of 
receptors other than CD16, we decided to evaluate the expression of NKp30 on CIK cells by flow 
cytometry analysis. Figure 22 A shows one representative experiment in which CIK cells were 
stained with anti-NKp30 and an isotype control antibodies, showing a remarkable expression of the 
receptor on CD3+CD56+ cells. On the other hand, we had already assessed that NKG2D is expressed 
on almost all CD3+CD56+ cells (Figure 1 B). 
Therefore, target cells were incubated with bispecific antibodies or immunoligands that target Her2 
on target cells and CD3, NKG2D or NKp30 on CIK cells, and used in 51Cr-release assays. The 
engagement of CD3 with the CD3xHer2 bispecific scFv produced an outstanding enhancement of 
killing, which resulted to be even higher than that obtained by trastuzumab. The increase of activity 
was antigen-specific, as the control CD3-specific bispecific scFv targeting CD20 was not able to 
induce target cell killing. On the contrary, the engagement of NKG2D and NKp30 did not produce a 
significant enhancement of activity, suggesting that the signals transduced through these molecules 
are not sufficient to enhance CIK cell cytotoxicity on their own (Figure 22 B). 
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Figure 22: CIK cell cytotoxicity is enhanced by bispecific antibodies. CIK cells were 
analyzed for their NKp30 expression by flow cytometry. (A) Gating strategy on 
CD3+CD56+ CIK cells for the evaluation of NKp30 expression on double-positive 
cells. Bulk cultures were first gated for CD3 and CD56 co-espression to identify the 
CIK subset (left panel), followed by analysis of NKp30 expression (right panel). (B) 
Lytic activity of CIK cells was measured between day 14 and 21 of the culture by 
51Cr-release assay against the SKOV-3 tumor cell line, combining effector cells with 
scaling concentrations of Her2xCD3 (black columns), CD20xCD3 (grey columns), 
ULBP2xHer2 (striped columns), B7H6xHer2 (oblique striped columns) bispecific 
antibodies. Trastuxumab (white columns) and rituximab (dotted columns) served as 
controls. Data shown are the mean percentage ± SD of specific lysis at an 
effector/target ratio of 50:1. Data were analyzed by one-way ANOVA (*** or §§§, P 
≤ 0.001; **, ## or §§, P ≤ 0.01; *, # or §, P ≤ 0.05; not statistically significant (P > 
0.05) if not indicated). 
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DISCUSSION 
Recent years have witnessed a renewed interest for immunotherapy in cancer, mainly due to the 
successes of checkpoint inhibitors81, and ACT with CAR-redirected T cells10. These latter, in 
particular in hematological malignancies, outperformed previous strategies involving the infusion of 
ex vivo expanded TIL11 or  NK cells12. However, the genetic manipulation required for the 
obtainment of CAR-modified T cells and the extremely high costs for their production represent a 
strong limitation to the wide clinical diffusion of this approach. These obstacles could be overcome 
by using CIK cells, a population of effector cells obtained from PBMCs after ex vivo stimulation, 
which show unique and interesting features supporting their role as a promising tool for ACT 
approaches. 
In this study, CIK cells were obtained from healthy donor PBMCs according to standard protocols18–
20. Phenotype of the CD3+CD56+ subpopulation was evaluated by cytometry analysis and results 
essentially confirmed the already reported phenotype21,23–25. In particular, CD3+CD56+ CIK cells are 
mostly CD8+, and express a functional TCR that is responsive to specific MHC-dependent stimuli but 
not directly involved in tumor cell killing24. On the other hand, CIK cells are characterized by high 
levels of NKG2D that is considered the main mediator of their antitumor activity, as it binds MICA/B 
and members of the ULBP family, leading to target cell recognition and lysis25. Moreover, we 
detected high levels of CD11, which is a requisite for target cell binding and lysis24.  
Furthermore, we characterized the functional activity of CIK cells against 23 different tumor samples 
comprising both primary and tumor cell line specimens derived from a broad range of different 
histotypes, and demonstrated a high antitumor potential for CIK cells. To carry out functional assays 
against such a large number of target cells, we expanded 97 different CIK cell cultures and for 60 of 
these we had the possibility to carry out a thorough analysis of the phenotype. To the best of our 
knowledge, this is the first report with such a high number of donors tested. Flow cytometry results 
highlighted a remarkable and donor-dependent expression of CD16 on CD3+CD56+ cells. In this 
regard, there is not a full agreement about the expression of CD16 on CIK cells, since some groups 
reported that CIK cells do not express this receptor20,21,82, while others detected its expression at 
some extent, but did not further investigated such issue80,83. Pievani et al. reported that CIK cells 
present a dual functional ability to kill tumors, through either T cell-like TCR-dependent or NK cell-
like NKG2D-mediated mechanisms24. Based on our phenotypical observations, we were prompted to 
investigate the potential functional relevance of CD16 in improving the CIK cells intrinsic cytotoxic 
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activity, when combined with antitumor therapeutic mAbs to exert ADCC phenomena. Indeed, it has 
been widely accepted that ADCC plays an essential role in mediating the antitumor effects of 
therapeutic mAbs routinely used in the treatment of cancer, such as trastuzumab and 
cetuximab43,84. The combination of mAbs with CIK cells produced a significant antigen-specific 
increase of cytotoxicity that was consistent with Her2 and EGFR expression on target cells. The 
direct involvement of CD16 was demonstrated by using a blocking monoclonal antibody against the 
CD16, which was able to bring about the cytotoxicity to return to the basal levels, thus indicating 
that the CD16 receptor is functional and directly involved in the ADCC. An important observation is 
the CIK cell ability to increase the cytotoxic activity irrespective to the levels of CD16 expressed. This 
finding suggest that even a small fraction of CD16+ CIK cells can exert a relevant ADCC activity, likely 
due to the recycling potentialities of the effectors, and leads to a significant enhancement of the 
whole population cytotoxicity. Translated into a potential clinical application, this aspect could 
represent a critical issue, since patients generating CIK cell cultures with even a low expression of 
CD16 might strongly benefit from CIK and mAbs combination therapy.  
Another relevant aspect is that most of the CIK cell studies reported in literature, including clinical 
trials of adoptive immunotherapy, used bulk-expanded CIK cultures where NK cells were still present 
as contaminants. To exclude that the ADCC activity observed was due to the presence of a residual 
NK subpopulation, NK cells were removed from cultures by immunomagnetic depletion with a mAb 
against NKp4678,79. Performing a depletion for NKp46, instead of a positive selection using CD5, 
which is not expressed by NK cells85, allowed us to obtain “untouched” CIK cells, thus preventing 
unwanted nonspecific effector cell stimulation in the subsequent cytotoxicity assays. Analysis of lytic 
activity confirmed that the ADCC phenomena observed are accountable to the CD3+CD56+CD16+ 
subpopulation, confirming for the first time that CIK cells can induce ADCC by the engagement of 
CD16. This result was further supported by in vivo experiments using human ovarian carcinoma 
xenografts in NSG mice, in which the co-administration of CIK cells and mAbs significantly increased 
the survival of treated mice. The inefficacy of the treatment with CIK cells as a single agent is 
consistent with our in vitro results, and mostly with reports from other groups where SKOV-3 cells 
have been described to be resistant to CIK cell-mediated killing83,86,87. Nevertheless, when treated 
with the combination of CIK cells and mAbs, even these resistant cells become responsive to 
therapy. 
Overall, we advance that the combination of adoptive CIK cell therapy with clinical-grade mAbs can 
be proposed as a very promising strategy to improve the therapeutic approaches against different 
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types of tumors. Indeed, several clinical studies demonstrated the feasibility and high tolerability of 
CIK cell infusions36, and moreover trastuzumab and cetuximab are well established and widely used 
in clinical practice; therefore, no particular safety and clinical concerns should be raised for this 
combination approach. 
 This novel strategy we advance could address one of the critical issues of current adoptive 
immunotherapy approaches, i.e. the rapid obtainment of sufficient numbers of targeted effector 
cells to be administered. Indeed, CIK cells are easy to produce and do not require genetic 
manipulations for expansion; moreover, the relevant enhancement of CIK antitumor potential 
mediated by mAb combination could allow to reduce the total cell dose and the number of infusions 
required for treatment, with positive implications for patients with limited ex vivo expansion rates of 
CIK cells17. Furthermore, the finding of no correlation between the expression level of CD16 on CIK 
cells and the cytotoxicity outcome when combined with mAbs, further broadens the number of 
patients that could potentially benefit from this therapy.  
Moreover, the results reported in this work open additional opportunities to further improve CIK 
cell antitumor activity. Indeed, the combination of CIK cells with Fc-engineered antibodies 
demonstrated that tumor cell killing depends on an antigen-specific recruitment of CIK cells, and 
that a higher binding affinity between CD16 and mAbs is capable of leading to an increased 
cytotoxicity. Another promising strategy to improve CIK cell antitumor activity relies on the 
combination with bispecific antibodies, which have the potential to activate and trigger effector cells 
also through the engagement of receptors other than CD16, such as CD3 and NKp30. Importantly, 
when using bispecific antibodies, concomitant engagement of both the triggering molecule on CIK 
cells, and the tumor antigen on target cells is necessary to induce CIK cell cytotoxicity, thus assuring 
a safety mechanism for unwanted non-specific activation. 
In conclusion, we demonstrated for the first time that CIK cells express CD16 in a donor-dependent 
manner, and that the concurrent administration of therapeutic mAbs, such as trastuzumab or 
cetuximab, leads to a significant improvement of their antitumor activity, triggering a potent ADCC 
activity. Additionally, the modification of the Fc region of mAbs increases their binding affinity to 
CD16 and enhances CIK cell cytotoxicity. Moreover, these cells can also be triggered by the 
engagement of alternative activating receptors, producing a further enhancement of antitumor 
activity. Taken together, the results produced in this study describe a novel function of CIK cells, 
which confirm their outstanding potential as a promising tool for ACT approaches. These data lead 
us to envisage new perspectives for adoptive immunotherapy where antigen-specific retargeting of 
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T cells can be achieved by the simple combination of non antigen-specific effector cells and tumor-
specific mAbs, already widely employed in clinical practice.  
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ABBREVIATIONS 
ACT Adoptive cell transfer 
ADCC Antibody-Dependent Cell-mediated Cytotoxicity 
B7-H6 B7 homolog 6 
BLI Bioluminescence imaging 
BsAb Bispecific Antibody 
CAR Chimeric antigen receptor 
CH1 or 2 Constant domain 1 or 2 of the Heavy chain 
CIK Cytokine Induced Killer cells 
E/T ratio Effector/Target ratio 
EGFR Human epidermal growth factor 1 
Fab region Fragment antigen-binding region 
Fc region Fragment crystallizable region 
FcR Fc receptor 
GVHD Graft versus host disease 
Her-2 Human epidermal growth factor 2 
i.p. Intraperitoneal 
IFN- Interferon- 
IgG Immunoglobulin G 
IL-2 Interleukin-2 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif 
KO Knockout 
luc Luciferase gene 
mAbs Monoclonal Antibodies 
MHC Major Histocompatibility Complex 
NKG2D Natural-Killer group 2 member D 
NSG NOD/SCID common  chain knockout 
PBMCs Pheripheral Blood Mononuclear Cells 
scFv Single chain fragment variable 
ULBP UL-16 binding protein 
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